-DOCSTART-	O

Title	O
:	O
Rationale	O
and	O
design	O
for	O
the	O
study	O
of	O
rivaroxaban	B-I
to	O
reduce	O
thrombotic	O
events	O
,	O
hospitalization	O
and	O
death	O
in	O
outpatients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
The	O
PREVENT	O
-	O
HD	O
study	O
.	O

METHODS	O
:	O
PREVENT	O
-	O
HD	O
is	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
pragmatic	O
,	O
event	O
-	O
driven	O
phase	O
3	O
trial	O
to	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
rivaroxaban	B-I
in	O
symptomatic	B-P
outpatients	I-P
with	I-P
laboratory	I-P
-	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
at	I-P
risk	I-P
for	I-P
thrombotic	I-P
events	I-P
,	I-P
hospitalization	I-P
,	I-P
and	I-P
death	I-P
.	O

Several	O
challenges	O
posed	O
by	O
the	O
pandemic	O
have	O
necessitated	O
innovative	O
approaches	O
to	O
clinical	O
trial	O
design	O
,	O
start	O
-	O
up	O
,	O
and	O
conduct	O
.	O

Participants	O
are	O
randomized	O
in	O
a	O
1	O
:	O
1	O
ratio	O
,	O
stratified	O
by	O
time	O
from	O
COVID	O
-	O
19	O
confirmation	O
,	O
to	O
either	O
rivaroxaban	B-I
10	O
mg	O
once	O
daily	O
or	O
placebo	B-C
for	O
35	O
days	O
.	O

The	O
primary	O
efficacy	O
end	O
point	O
is	O
a	B-O
composite	I-O
of	I-O
symptomatic	I-O
venous	I-O
thromboembolism	I-O
,	O
myocardial	B-O
infarction	I-O
,	O
ischemic	B-O
stroke	I-O
,	O
acute	B-O
limb	I-O
ischemia	I-O
,	O
non	B-O
-	I-O
central	I-O
nervous	I-O
system	I-O
systemic	I-O
embolization	I-O
,	O
all	B-O
-	I-O
cause	I-O
hospitalization	I-O
,	O
and	O
all	B-O
-	I-O
cause	I-O
mortality	I-O
.	O

The	O
primary	O
safety	O
end	O
point	O
is	O
fatal	B-O
and	O
critical	B-O
site	I-O
bleeding	I-O
according	O
to	O
the	B-O
International	I-O
Society	I-O
on	I-O
Thrombosis	I-O
and	I-O
Haemostasis	I-O
definition	I-O
.	O

Enrollment	O
began	O
in	O
August	O
2020	O
and	O
is	O
expected	O
to	O
enroll	O
approximately	O
4	O
,	O
000	O
participants	O
to	O
yield	O
the	O
required	O
number	O
of	O
end	O
point	O
events	O
.	O

-DOCSTART-	O

Title	O
:	O
A	O
Phase	O
II	O
Safety	O
and	O
Efficacy	O
Study	O
on	O
Prognosis	O
of	O
Moderate	O
Pneumonia	O
in	O
Coronavirus	B-P
Disease	I-P
2019	I-P
Patients	I-P
With	O
Regular	B-I
Intravenous	I-I
Immunoglobulin	I-I
Therapy	I-I
.	O

METHODS	O
:	O
An	O
open	O
-	O
label	O
,	O
multicenter	O
,	O
comparative	O
,	O
randomized	O
study	O
was	O
conducted	O
on	O
COVID	B-P
-	I-P
19	I-P
patients	I-P
with	I-P
moderate	I-P
pneumonia	I-P
.	O

One	B-P
hundred	I-P
eligible	I-P
patients	I-P
were	O
randomized	O
in	O
1	O
:	O
1	O
ratio	O
either	O
to	O
receive	O
IVIG	B-I
+	O
standard	B-I
of	I-I
care	I-I
(	I-I
SOC	I-I
)	I-I
or	O
SOC	B-C
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
a	B-I
Single	I-I
High	I-I
Dose	I-I
of	I-I
Vitamin	I-I
D3	I-I
on	O
Hospital	O
Length	O
of	O
Stay	O
in	O
Patients	B-P
With	I-P
Moderate	I-P
to	I-P
Severe	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
conducted	O
in	O
2	O
sites	O
in	O
Sao	O
Paulo	O
,	O
Brazil	O
.	O

The	O
study	O
included	O
240	B-P
hospitalized	I-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
who	I-P
were	I-P
moderately	I-P
to	I-P
severely	I-P
ill	I-P
at	I-P
the	I-P
time	I-P
of	I-P
enrollment	I-P
from	I-P
June	I-P
2	I-P
,	I-P
2020	I-P
,	I-P
to	I-P
August	I-P
27	I-P
,	I-P
2020	I-P
.	I-P

The	I-P
final	I-P
follow	I-P
-	I-P
up	I-P
was	I-P
on	I-P
October	I-P
7	I-P
,	I-P
2020	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
a	B-I
single	I-I
oral	I-I
dose	I-I
of	I-I
200	I-I
000	I-I
IU	I-I
of	I-I
vitamin	I-I
D3	I-I
(	O
n	O
=	O
120	O
)	O
or	O
placebo	B-C
(	O
n	O
=	O
120	O
)	O
.	O

The	O
primary	O
outcome	O
was	O
length	B-O
of	I-O
stay	I-O
,	O
defined	O
as	O
the	B-O
time	I-O
from	I-O
the	I-O
date	I-O
of	I-O
randomization	I-O
to	I-O
hospital	I-O
discharge	I-O
.	O

Prespecified	O
secondary	O
outcomes	O
included	O
mortality	B-O
during	O
hospitalization	O
;	O
the	B-O
number	I-O
of	I-O
patients	I-O
admitted	I-O
to	I-O
the	I-O
intensive	I-O
care	I-O
unit	I-O
;	O
the	B-O
number	I-O
of	I-O
patients	I-O
who	I-O
required	I-O
mechanical	I-O
ventilation	I-O
and	O
the	B-O
duration	I-O
of	I-O
mechanical	I-O
ventilation	I-O
;	O
and	O
serum	B-O
levels	I-O
of	I-O
25	I-O
-	I-O
hydroxyvitamin	I-O
D	I-O
,	O
total	B-O
calcium	I-O
,	O
creatinine	B-O
,	O
and	O
C	B-O
-	I-O
reactive	I-O
protein	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Randomized	O
placebo	O
-	O
controlled	O
pilot	O
clinical	O
trial	O
on	O
the	O
efficacy	O
of	O
ayurvedic	B-I
treatment	I-I
regime	I-I
on	O
COVID	B-P
-	I-P
19	I-P
positive	I-P
patients	I-P
.	O

METHODS	O
:	O
It	O
is	O
a	O
placebo	O
controlled	O
randomized	O
double	O
-	O
blind	O
pilot	O
clinical	O
trial	O
.	O

The	O
study	O
was	O
registered	O
with	O
Clinical	O
Trial	O
Registry	O
-	O
India	O
(	O
vide	O
Registration	O
No	O
.	O

CTRI	O
/	O
2020/05/025273	O
)	O
and	O
conducted	O
at	O
the	O
Department	O
of	O
Medicine	O
in	O
National	O
Institute	O
of	O
Medical	O
Sciences	O
and	O
Research	O
,	O
Jaipur	O
,	O
India	O
.	O

1	B-I
g	I-I
of	I-I
Giloy	I-I
Ghanvati	I-I
(	O
Tinospora	B-I
cordifolia	I-I
)	O
and	O
2	B-I
g	I-I
of	I-I
Swasari	I-I
Ras	I-I
(	O
traditional	B-I
herbo	I-I
-	I-I
mineral	I-I
formulation	I-I
)	O
and	O
0	B-I
.	I-I
5	I-I
g	I-I
each	I-I
of	I-I
Ashwagandha	I-I
(	O
Withania	B-I
somnifera	I-I
)	O
and	O
Tulsi	B-I
Ghanvati	I-I
(	O
Ocimum	B-I
sanctum	I-I
)	O
were	O
given	O
orally	O
to	O
the	O
patients	O
in	O
treatment	O
group	O
twice	O
per	O
day	O
for	O
7	O
days	O
.	O

Medicines	O
were	O
given	O
in	O
the	O
form	O
of	O
tablets	O
and	O
each	O
tablet	O
weighed	O
500	O
mg	O
.	O

While	O
,	O
Swasari	B-I
Ras	I-I
was	O
administered	O
in	O
powdered	O
form	O
,	O
30	O
min	O
before	O
breakfasts	O
and	O
dinners	O
,	O
rest	O
were	O
scheduled	O
for	O
30	O
min	O
post	O
-	O
meals	O
.	O

Patients	O
in	O
the	O
treatment	O
group	O
also	O
received	O
4	B-I
drops	I-I
of	I-I
Anu	I-I
taila	I-I
(	O
traditional	O
nasal	O
drop	O
)	O
in	O
each	O
nostril	O
every	O
day	O
1	O
h	O
before	O
breakfast	O
.	O

Patients	O
in	O
the	B-C
placebo	I-C
group	O
received	O
identical	B-C
-	I-C
looking	I-C
tablets	I-C
and	O
drops	B-C
,	O
post	O
randomization	O
and	O
double	O
blinded	O
assortments	O
.	O

RT	B-O
-	I-O
qPCR	I-O
test	I-O
was	O
used	O
for	O
the	O
detection	O
of	O
viral	B-O
load	I-O
in	O
the	O
nasopharyngeal	O
and	O
oropharyngeal	O
swab	O
samples	O
of	O
study	O
participants	O
during	O
the	O
study	O
.	O

Chemiluminescent	B-O
immunometric	I-O
assay	I-O
was	O
used	O
to	O
quantify	O
serum	B-O
levels	I-O
of	I-O
interleukin	I-O
-	I-O
6	I-O
(	I-O
IL	I-O
-	I-O
6	I-O
)	I-O
,	O
tumor	B-O
necrosis	I-O
factor	I-O
alpha	I-O
(	I-O
TNF	I-O
-	I-O
?	I-O
)	I-O
and	O
high	B-O
sensitivity	I-O
C	I-O
-	I-O
reactive	I-O
protein	I-O
(	I-O
hs	I-O
-	I-O
CRP	I-O
)	I-O
on	O
day	O
1	O
and	O
day	O
7	O
of	O
the	O
study	O
.	O

-DOCSTART-	O

Title	O
:	O
Progesterone	B-I
in	O
Addition	O
to	O
Standard	B-I
of	I-I
Care	I-I
vs	O
Standard	B-C
of	I-C
Care	I-C
Alone	I-C
in	O
the	O
Treatment	O
of	O
Men	B-P
Hospitalized	I-P
With	I-P
Moderate	I-P
to	I-P
Severe	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
,	O
Controlled	O
Pilot	O
Trial	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
pilot	O
,	O
randomized	O
,	O
open	O
-	O
label	O
,	O
controlled	O
trial	O
of	O
subcutaneous	B-I
progesterone	I-I
in	O
men	B-P
hospitalized	I-P
with	I-P
confirmed	I-P
moderate	I-P
to	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
to	O
receive	O
SOC	B-I
plus	O
progesterone	B-I
(	O
100	O
mg	O
subcutaneously	O
twice	O
daily	O
for	O
up	O
to	O
5	O
days	O
)	O
or	O
SOC	B-C
alone	I-C
.	O

In	O
addition	O
to	O
assessment	O
of	O
safety	O
,	O
the	O
primary	O
outcome	O
was	O
change	O
in	O
clinical	B-O
status	I-O
on	O
day	O
7	O
.	O

Length	B-O
of	I-O
hospital	I-O
stay	I-O
and	O
number	B-O
of	I-O
days	I-O
on	I-O
supplemental	I-O
oxygen	I-O
were	O
key	O
secondary	O
outcomes	O
.	O

-DOCSTART-	O

Title	O
:	O
Tocilizumab	B-I
in	O
Hospitalized	B-P
Patients	I-P
with	I-P
Severe	I-P
Covid	I-P
-	I-P
19	I-P
Pneumonia	I-P
.	O

METHODS	O
:	O
In	O
this	O
phase	O
3	O
trial	O
,	O
we	O
randomly	O
assigned	O
patients	B-P
who	I-P
were	I-P
hospitalized	I-P
with	I-P
severe	I-P
Covid	I-P
-	I-P
19	I-P
pneumonia	I-P
in	O
a	O
2	O
:	O
1	O
ratio	O
receive	O
a	B-I
single	I-I
intravenous	I-I
infusion	I-I
of	I-I
tocilizumab	I-I
(	O
at	O
a	O
dose	O
of	O
8	O
mg	O
per	O
kilogram	O
of	O
body	O
weight	O
)	O
or	O
placebo	B-C
.	O

Approximately	O
one	O
quarter	O
of	O
the	O
participants	O
received	O
a	B-I
second	I-I
dose	I-I
of	I-I
tocilizumab	I-I
or	O
placebo	B-C
8	O
to	O
24	O
hours	O
after	O
the	O
first	O
dose	O
.	O

The	O
primary	O
outcome	O
was	O
clinical	B-O
status	I-O
at	O
day	O
28	O
on	O
an	B-O
ordinal	I-O
scale	I-O
ranging	O
from	O
1	O
(	O
discharged	O
or	O
ready	O
for	O
discharge	O
)	O
to	O
7	O
(	O
death	O
)	O
in	O
the	O
modified	O
intention	O
-	O
to	O
-	O
treat	O
population	O
,	O
which	O
included	O
all	O
the	O
patients	O
who	O
had	O
received	O
at	O
least	O
one	B-I
dose	I-I
of	I-I
tocilizumab	I-I
or	O
placebo	B-C
.	O

-DOCSTART-	O

Title	O
:	O
The	O
use	O
of	O
oxygen	B-I
hoods	I-I
in	O
patients	B-P
failing	I-P
on	I-P
conventional	I-P
high	I-P
-	I-P
flow	I-P
oxygen	I-P
delivery	I-P
systems	I-P
,	O
the	O
effects	O
on	O
oxygenation	O
,	O
mechanical	O
ventilation	O
and	O
mortality	O
rates	O
in	O
hypoxic	B-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
.	O

A	O
Prospective	O
Controlled	O
Cohort	O
Study	O
.	O

METHODS	O
:	O
DesignProspective	O
Controlled	O
Cohort	O
Study	O
.	O

SettingSingle	O
Center	O
.	O

ParticipantsAll	B-P
patients	I-P
admitted	I-P
with	I-P
a	I-P
diagnosis	I-P
of	I-P
COVID	I-P
-	I-P
19	I-P
were	O
reviewed	O
and	O
136	O
/	O
347	O
patients	O
met	O
inclusion	O
criteria	O
.	O

Study	O
period3	O
/	O
6	O
/	O
2020	O
to	O
5/1/2020	O
.	O

136	O
participants	O
completed	O
the	O
study	O
with	O
known	O
status	O
for	O
all	O
outcome	O
measures	O
.	O

Intervention	O
or	O
exposureOxygen	B-I
hoods	I-I
/	O
helmets	B-I
as	O
compared	O
to	O
conventional	B-C
high	I-C
-	I-C
flow	I-C
oxygen	I-C
delivery	I-C
systems	I-C
.	O

1	O
)	O
Pre	O
and	O
post	O
change	O
in	O
oxygen	B-O
saturation	I-O
(	I-O
SaO2	I-O
)	I-O
.	O

2	O
)	O
In	B-O
-	I-O
hospital	I-O
Mechanical	I-O
Ventilation	I-O
(	I-O
MV	I-O
)	I-O
.	O

3	O
)	O
In	B-O
-	I-O
hospital	I-O
Mortality	I-O
.	O

4	O
)	O
Length	B-O
of	I-O
hospitalization	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
guided	B-I
imagery	I-I
on	O
anxiety	O
,	O
muscle	O
pain	O
,	O
and	O
vital	O
signs	O
in	O
patients	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
randomized	O
controlled	O
trial	O
.	O

METHODS	O
:	O
110	B-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
were	O
recruited	O
and	O
randomly	O
assigned	O
to	O
two	O
control	O
and	O
intervention	O
groups	O
.	O

Data	O
were	O
collected	O
using	O
the	B-O
Spielberger	I-O
Anxiety	I-O
Inventory	I-O
,	O
the	B-O
McGill	I-O
Pain	I-O
Questionnaire	I-O
,	O
and	O
the	B-O
Visual	I-O
Analogue	I-O
Scale	I-O
.	O

The	O
intervention	O
group	O
received	O
ten	O
training	O
sessions	O
of	O
guided	B-I
imagery	I-I
.	O

-DOCSTART-	O

Title	O
:	O
Comparison	O
of	O
losartan	B-I
and	O
amlodipine	B-I
effects	O
on	O
the	O
outcomes	O
of	O
patient	B-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
primary	I-P
hypertension	I-P
:	O
A	O
randomised	O
clinical	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
randomised	O
clinical	O
trial	O
,	O
hospitalised	B-P
patients	I-P
with	I-P
COVID	I-P
-	I-P
19	I-P
and	I-P
primary	I-P
HTN	I-P
were	O
enrolled	O
in	O
the	O
study	O
.	O

One	O
arm	O
received	O
losartan	B-I
,	O
25	O
mg	O
,	O
twice	O
a	O
day	O
and	O
the	O
other	O
arm	O
received	O
amlodipine	B-I
,	O
5	O
mg	O
per	O
day	O
for	O
2	O
weeks	O
.	O

The	O
main	O
outcomes	O
were	O
compare	B-O
30	I-O
-	I-O
day	I-O
mortality	I-O
rate	I-O
and	O
length	B-O
of	I-O
hospital	I-O
stay	I-O
.	O

-DOCSTART-	O

Title	O
:	O
Early	B-I
versus	O
deferred	B-I
anti	I-I
-	I-I
SARS	I-I
-	I-I
CoV	I-I
-	I-I
2	I-I
convalescent	I-I
plasma	I-I
in	O
patients	B-P
admitted	I-P
for	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
randomized	O
phase	O
II	O
clinical	O
trial	O
.	O

-DOCSTART-	O

Title	O
:	O
Effect	O
of	O
Ivermectin	B-I
on	O
Time	O
to	O
Resolution	O
of	O
Symptoms	O
Among	O
Adults	B-P
With	I-P
Mild	I-P
COVID	I-P
-	I-P
19	I-P
:	O
A	O
Randomized	O
Clinical	O
Trial	O
.	O

METHODS	O
:	O
Double	O
-	O
blind	O
,	O
randomized	O
trial	O
conducted	O
at	O
a	O
single	O
site	O
in	O
Cali	O
,	O
Colombia	O
.	O

Potential	O
study	O
participants	O
were	O
identified	O
by	O
simple	O
random	O
sampling	O
from	O
the	O
state	O
'	O
s	O
health	O
department	O
electronic	O
database	O
of	O
patients	O
with	O
symptomatic	O
,	O
laboratory	O
-	O
confirmed	O
COVID	O
-	O
19	O
during	O
the	O
study	O
period	O
.	O

A	B-P
total	I-P
of	I-P
476	I-P
adult	I-P
patients	I-P
with	I-P
mild	I-P
disease	I-P
and	I-P
symptoms	I-P
for	I-P
7	I-P
days	I-P
or	I-P
fewer	I-P
(	I-P
at	I-P
home	I-P
or	I-P
hospitalized	I-P
)	I-P
were	O
enrolled	O
between	O
July	O
15	O
and	O
November	O
30	O
,	O
2020	O
,	O
and	O
followed	O
up	O
through	O
December	O
21	O
,	O
2020	O
.	O

Patients	O
were	O
randomized	O
to	O
receive	O
ivermectin	B-I
,	O
300	O
?g	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
for	O
5	O
days	O
(	O
n	O
=	O
200	O
)	O
or	O
placebo	B-C
(	O
n	O
=	O
200	O
)	O
.	O

Primary	O
outcome	O
was	O
time	B-O
to	I-O
resolution	I-O
of	I-O
symptoms	I-O
within	O
a	O
21	O
-	O
day	O
follow	O
-	O
up	O
period	O
.	O

Solicited	B-O
adverse	I-O
events	I-O
and	O
serious	B-O
adverse	I-O
events	I-O
were	O
also	O
collected	O
.	O

-DOCSTART-	O

Title	O
:	O
Tocilizumab	B-I
plus	O
standard	B-I
care	I-I
versus	O
standard	B-C
care	I-C
in	O
patients	B-P
in	I-P
India	I-P
with	I-P
moderate	I-P
to	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
-	I-P
associated	I-P
cytokine	I-P
release	I-P
syndrome	I-P
(	O
COVINTOC	O
)	O
:	O
an	O
open	O
-	O
label	O
,	O
multicentre	O
,	O
randomised	O
,	O
controlled	O
,	O
phase	O
3	O
trial	O
.	O

METHODS	O
:	O
COVINTOC	O
is	O
an	O
open	O
-	O
label	O
,	O
multicentre	O
,	O
randomised	O
,	O
controlled	O
,	O
phase	O
3	O
trial	O
done	O
at	O
12	O
public	O
and	O
private	O
hospitals	O
across	O
India	O
.	O

Adults	B-P
(	I-P
aged	I-P
?18	I-P
years	I-P
)	I-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
moderate	I-P
to	I-P
severe	I-P
COVID	I-P
-	I-P
19	I-P
(	I-P
Indian	I-P
Ministry	I-P
of	I-P
Health	I-P
grading	I-P
)	I-P
confirmed	I-P
by	I-P
positive	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
PCR	I-P
result	I-P
were	O
randomly	O
assigned	O
(	O
1	O
:	O
1	O
block	O
randomisation	O
)	O
to	O
receive	O
tocilizumab	B-I
6	O
mg	O
/	O
kg	O
plus	O
standard	B-I
care	I-I
(	O
the	B-I
tocilizumab	I-I
group	O
)	O
or	O
standard	B-C
care	I-C
alone	I-C
(	O
the	B-C
standard	I-C
care	I-C
group	O
)	O
.	O

The	O
primary	O
endpoint	O
was	O
progression	B-O
of	I-O
COVID	I-O
-	I-O
19	I-O
(	O
from	O
moderate	O
to	O
severe	O
or	O
from	O
severe	O
to	O
death	O
)	O
up	O
to	O
day	O
14	O
in	O
the	O
modified	O
intention	O
-	O
to	O
-	O
treat	O
population	O
of	O
all	O
participants	O
who	O
had	O
at	O
least	O
one	O
post	O
-	O
baseline	O
assessment	O
for	O
the	O
primary	O
endpoint	O
.	O

Safety	B-O
was	O
assessed	O
in	O
all	O
randomly	O
assigned	O
patients	O
.	O

The	O
trial	O
is	O
completed	O
and	O
registered	O
with	O
the	O
Clinical	O
Trials	O
Registry	O
India	O
(	O
CTRI	O
/	O
2020/05/025369	O
)	O
.	O

-DOCSTART-	O

Title	O
:	O
Sarilumab	B-I
in	O
patients	B-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
severe	I-P
or	I-P
critical	I-P
COVID	I-P
-	I-P
19	I-P
:	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
phase	O
3	O
trial	O
.	O

METHODS	O
:	O
We	O
did	O
a	O
60	O
-	O
day	O
,	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
multinational	O
phase	O
3	O
trial	O
at	O
45	O
hospitals	O
in	O
Argentina	O
,	O
Brazil	O
,	O
Canada	O
,	O
Chile	O
,	O
France	O
,	O
Germany	O
,	O
Israel	O
,	O
Italy	O
,	O
Japan	O
,	O
Russia	O
,	O
and	O
Spain	O
.	O

We	O
included	O
adults	B-P
(	I-P
?18	I-P
years	I-P
)	I-P
admitted	I-P
to	I-P
hospital	I-P
with	I-P
laboratory	I-P
-	I-P
confirmed	I-P
SARS	I-P
-	I-P
CoV	I-P
-	I-P
2	I-P
infection	I-P
and	I-P
pneumonia	I-P
,	I-P
who	I-P
required	I-P
oxygen	I-P
supplementation	I-P
or	I-P
intensive	I-P
care	I-P
.	O

Patients	O
were	O
randomly	O
assigned	O
(	O
2:2:1	O
with	O
permuted	O
blocks	O
of	O
five	O
)	O
to	O
receive	O
intravenous	B-I
sarilumab	I-I
400	O
mg	O
,	O
sarilumab	B-I
200	O
mg	O
,	O
or	O
placebo	B-C
.	O

Patients	O
,	O
care	O
providers	O
,	O
outcome	O
assessors	O
,	O
and	O
investigators	O
remained	O
masked	O
to	O
assigned	O
intervention	O
throughout	O
the	O
course	O
of	O
the	O
study	O
.	O

The	O
primary	O
endpoint	O
was	O
time	B-O
to	I-O
clinical	I-O
improvement	I-O
of	I-O
two	I-O
or	O
more	B-O
points	I-O
(	O
seven	O
point	O
scale	O
ranging	O
from	O
1	O
[	O
death	O
]	O
to	O
7	O
[	O
discharged	O
from	O
hospital	O
]	O
)	O
in	O
the	O
modified	O
intention	O
-	O
to	O
-	O
treat	O
population	O
.	O

The	O
key	O
secondary	O
endpoint	O
was	O
proportion	B-O
of	I-O
patients	I-O
alive	I-O
at	O
day	O
29	O
.	O

Safety	O
outcomes	O
included	O
adverse	B-O
events	I-O
and	O
laboratory	B-O
assessments	I-O
.	O

This	O
study	O
is	O
registered	O
with	O
ClinicalTrials	O
.	O
gov	O
,	O
NCT04327388	O
;	O
EudraCT	O
,	O
2020-001162-12	O
;	O
and	O
WHO	O
,	O
U1111	O
-	O
1249	O
-	O
6021	O
.	O

-DOCSTART-	O

Title	O
:	O
Azithromycin	B-I
for	O
community	O
treatment	O
of	O
suspected	O
COVID	O
-	O
19	O
in	O
people	B-P
at	I-P
increased	I-P
risk	I-P
of	I-P
an	I-P
adverse	I-P
clinical	I-P
course	I-P
in	I-P
the	I-P
UK	I-P
(	O
PRINCIPLE	O
)	O
:	O
a	O
randomised	O
,	O
controlled	O
,	O
open	O
-	O
label	O
,	O
adaptive	O
platform	O
trial	O
.	O

METHODS	O
:	O
In	O
this	O
UK	O
-	O
based	O
,	O
primary	O
care	O
,	O
open	O
-	O
label	O
,	O
multi	O
-	O
arm	O
,	O
adaptive	O
platform	O
randomised	O
trial	O
of	O
interventions	O
against	O
COVID	O
-	O
19	O
in	O
people	B-P
at	I-P
increased	I-P
risk	I-P
of	I-P
an	I-P
adverse	I-P
clinical	I-P
course	I-P
(	O
PRINCIPLE	O
)	O
,	O
we	O
randomly	O
assigned	O
people	B-P
aged	I-P
65	I-P
years	I-P
and	I-P
older	I-P
,	I-P
or	I-P
50	I-P
years	I-P
and	I-P
older	I-P
with	I-P
at	I-P
least	I-P
one	I-P
comorbidity	I-P
,	I-P
who	I-P
had	I-P
been	I-P
unwell	I-P
for	I-P
14	I-P
days	I-P
or	I-P
less	I-P
with	I-P
suspected	I-P
COVID	I-P
-	I-P
19	I-P
,	O
to	O
usual	B-I
care	I-I
plus	O
azithromycin	B-I
500	O
mg	O
daily	O
for	O
three	O
days	O
,	O
usual	B-I
care	I-I
plus	O
other	B-I
interventions	I-I
,	O
or	O
usual	B-C
care	I-C
alone	I-C
.	O

The	O
trial	O
had	O
two	O
coprimary	O
endpoints	O
measured	O
within	O
28	O
days	O
from	O
randomisation	O
:	O
time	B-O
to	I-O
first	I-O
self	I-O
-	I-O
reported	I-O
recovery	I-O
,	O
analysed	O
using	O
a	O
Bayesian	O
piecewise	O
exponential	O
,	O
and	O
hospital	B-O
admission	I-O
or	O
death	B-O
related	I-O
to	I-O
COVID	I-O
-	I-O
19	I-O
,	O
analysed	O
using	O
a	O
Bayesian	O
logistic	O
regression	O
model	O
.	O

Eligible	O
participants	O
with	O
outcome	O
data	O
were	O
included	O
in	O
the	O
primary	O
analysis	O
,	O
and	O
those	O
who	O
received	O
the	O
allocated	O
treatment	O
were	O
included	O
in	O
the	O
safety	O
analysis	O
.	O

The	O
trial	O
is	O
registered	O
with	O
ISRCTN	O
,	O
ISRCTN86534580	O
.	O

-DOCSTART-	O

Title	O
:	O
Efficacy	O
and	O
safety	O
of	O
pegylated	B-I
interferon	I-I
alfa	I-I
-	I-I
2	I-I
b	I-I
in	O
moderate	O
COVID	O
-	O
19	O
:	O
A	O
phase	O
II	O
,	O
randomized	O
,	O
controlled	O
,	O
open	O
-	O
label	O
study	O
.	O

METHODS	O
:	O
In	O
this	O
phase	O
2	O
,	O
randomized	O
,	O
open	O
-	O
label	O
study	O
,	O
adult	B-P
subjects	I-P
aged	I-P
?18	I-P
years	I-P
with	I-P
RT	I-P
-	I-P
PCR	I-P
confirmed	I-P
COVID	I-P
-	I-P
19	I-P
with	I-P
moderate	I-P
symptoms	I-P
were	O
randomized	O
in	O
a	O
1	O
:	O
1	O
to	O
receive	O
PEG	B-I
IFN	I-I
-	I-I
?2b	I-I
plus	O
SOC	B-I
,	O
or	O
SOC	B-C
alone	I-C
.	O

The	O
primary	O
endpoint	O
was	O
improvement	O
in	O
clinical	B-O
status	I-O
on	O
day	O
15	O
,	O
measured	O
by	O
the	B-O
WHO	I-O
7	I-O
-	I-O
point	I-O
ordinal	I-O
scale	I-O
.	O

